This week on the FLATLINING Podcast, Ron and Matthew discuss two recent judicial decisions that contradict. A judge in Texas ruled that mifepristone, the drug used for over half of all abortions in the United States, should lose its approval status from the Food and Drug Administration (FDA). Then, on the same day, a judge in Washington ruled that the FDA needs to make the drug more widely available and stop some of its restrictions and warnings.
What do these decisions mean for drug manufacturers and the independent practice of medicine?
Plus: California backs off of Walgreens and CMS throws some pennies at hospitals.
Articles mentioned in this episode: